Rakesh Patel Net Worth

Rakesh Patel biography

Dr. Rakesh Patel serves as Independent Director of the Company. He has served as medical director of Radiation Oncology and Chair of the Multi-Disciplinary Breast Care Program at Good Samaritan Hospital since July 2013. In addition, he has served as co-founder of the TME Breast Care Network, a high-end physician peer-to-peer knowledge-sharing, research, education and consulting company, since January 2013. Dr. Patel has also served as Chief Executive Officer of Precision Cancer Specialists Medical Group, an organization whose core mission is to improve quality and access to advanced, targeted radiation therapy, since December 2016. He previously served on the board of directors of Radion, Inc., a company that improved quality of access for patients and doctors with an innovative e-collaboration platform, the assets of which were acquired by the Company in July 2014. Prior to that, Dr. Patel was the founder and served on the board of directors of BrachySolutions, Inc. (acquired by Radion Inc.), a telehealth company focused on improving quality and access to advanced brachytherapy globally via custom e-learning modules. He holds a Bachelor of Science degree from the University of Notre Dame and an M.D. from Indiana University School of Medicine. Dr. Patel completed his radiation oncology residency at the University of Wisconsin-Madison.

What is the salary of Rakesh Patel?

As the Independent Director of Icad Inc, the total compensation of Rakesh Patel at Icad Inc is $57,001. There are 8 executives at Icad Inc getting paid more, with Michael S. Klein having the highest compensation of $621,021.

How old is Rakesh Patel?

Rakesh Patel is 47, he's been the Independent Director of Icad Inc since 2018. There are 11 older and no younger executives at Icad Inc. The oldest executive at Icad Inc is Michael S. Klein, 67, who is the Exec. Chairman & CEO.

What's Rakesh Patel's mailing address?

Rakesh's mailing address filed with the SEC is C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA, NH, 03062.

Insiders trading at Icad Inc

Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton, and Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.

What does Icad Inc do?

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.

Icad Inc executives and stock owners

Icad Inc executives and other stock owners filed with the SEC include:

• Michael S. Klein,
  Exec. Chairman & CEO
• Stacey Stevens,
  President
• Jonathan Go,
  Chief Technology Officer
• Michael Klein,
  Executive Chairman of the Board, Chief Executive Officer
• Stacey M. Stevens,
  Pres
• Jonathan Go,
  Chief Technology Officer
• Andrew Sassine,
  Independent Director
• Susan Wood,
  Independent Director
• Rakesh Patel,
  Independent Director
• Jeremy Feffer,
  Investor Relations Contact Officer
• Nathaniel Dalton,
  Independent Director
• R. Scott Areglado,
  Chief Financial Officer
• Jeffrey Sirek,
  Chief Commercial Officer
• Brian Testa,
  Chief People Officer
• Annette L. Heroux,
  VP of Admin.
• Charles Ross Carter,
  CFO & Sec.
• Rachel Brem,
  Director
• Steven N Rappaport,
  Director
• Robert L Goodman,
  Director
• Dr Lawrence Howard,
  Director
• Anthony F Ecock,
  Director
• Timothy Norris Irish,
  Director
• Richard Christopher,
  Executive VP and CFO
• Andy Sassine,
  Director
• Somu Subramaniam,
  Director
• Elliot J Md Mba Sussman,
  Director
• Kenneth M Ferry,
  President, CEO
• James Harlan,
  Director
• George P Farley,
  Director
• W Scott Parr,
  Chief Executive Officer, Presi
• Herschell Sklaroff,
  Director
• John De Biase,
  Vice President of Sales
• Annette Heroux,
  Chief Financial Officer
• Steven K Rogers,
  Chief Scientific Officer
• Peter Farrell,
  EVP Marketing
• Thomas E Shoup,
  VP, Staff Operations
• James L Corbett,
  Chief Commercial Officer
• Kevin Woods,
  Vice President, Research & Dev
• Samuel Ronci,
  Vice President of Operations
• Robert Howard,
  Director
• Kevin C Burns,
  Executive VP of Finance, CFO
• Darlene M Deptula Hicks,
  Executive VP of Finance, CFO
• Maha Sallam,
  Executive Vice President
• Jeffrey H Barnes,
  Executive VP of Sales
• Dana R Brown,
  See Remarks
• Charles Ross Carter,
  CHIEF FINANCIAL OFFICER
• Hedvig Hricak,
  Director
• Daniel Joseph Shea,
  See Remarks
• Eric Lonnqvist,
  See Remarks
• Michael John Doyle,
  Director